Peptides by goal · Weight, muscle and energy
Peptides for growth hormone, ranked by evidence
Checked against our library and study pagesPublished by PepVault
Of the 13 compounds in our library linked to growth hormone, 12 have been studied in people for it (1 FDA-approved for a related use), 1 has animal or lab evidence only, and none rests on community reports alone. None has a study page of ours in people on growth hormone yet; HGH ranks first on the evidence its entry cites.
Peptides and growth hormone
Growth hormone peptides prompt the pituitary gland to release more of the body’s own growth hormone, which in turn raises IGF-1. This is the goal where the effect is easiest to measure, because growth hormone and IGF-1 levels show up in a blood test. Growth hormone itself (HGH), the approved medicine, is on this page too, as the point the others are measured against.
For growth hormone, a rise in the hormone or in IGF-1 is the measured result; the changes people want from it, such as more muscle or less fat, are a further step that most studies did not test.

The 13 compounds, ranked by evidence
FDA-approved for a related use
1 compound
HGH
#1 · FDA-approvedRecombinant human growth hormone — an identical copy of the GH your pituitary makes. It stimulates IGF-1 production, fat burning, muscle protein synthesis and tissue repair. For growth hormone it sits on the top rung: the library records an FDA approval for a related use, and 0 of our study pages in people cover it.
From its library entry: “FDA-approved since the 1980s for GH deficiency and several growth disorders, but not for aging or athletic use: in healthy adults, trials show about 2 kg of fat swapped for lean mass, with no strength gain and more side effects.”
What FDA approved it for, from the labels (read Nov 18, 2026): Humatrope (injection) for growth failure in children who make too little growth hormone and several other causes of short stature, and growth hormone deficiency in adults. HGH: legal and regulatory status
Why it is here: its library entry lists “Growth hormone”.
Studied in people
11 compounds
GHRP-2
#2 · Human studiesA potent growth hormone secretagogue: more potent than Ipamorelin but less selective, so along with GH and IGF-1 it also raises cortisol and prolactin. Approved in Japan only as a diagnostic test for GH deficiency. For growth hormone it has been studied in people: 4 of our study pages in people are about it.
GHRP-2: 30-day infusion raised GH and IGF-I in older adultsOur study page: clinical trial in people, 2004
- GHRP-2 plus L-arginine gave the biggest GH rise during exercise
- GHRP-2: stronger GH release than GHRH in 6 healthy young adults
- GHRP-2: chronic dosing made GH response to GHRH combo synergistic
Why it is here: its library entry lists “Strong GH release” and “IGF-1 boost” and 4 of our study pages are about this goal.
Hexarelin
#3 · Human studiesOne of the most powerful GH secretagogues, with a catch: the response fades. Hexarelin gives some of the largest GH spikes, but with daily use the response drops partly over weeks and recovers after a break. For growth hormone it has been studied in people: 3 of our study pages in people are about it, beside 1 animal or lab study (rats).
Hexarelin: GH response fell over 16 weeks, recovered after a breakOur study page: clinical trial in people, 12 people, 1998
- Hexarelin cut deep sleep and raised GH, ACTH, cortisol, prolactin
- Hexarelin kept its growth hormone effect over 60 days in old rats
- GHRP-2: stronger GH release than GHRH in 6 healthy young adults
Why it is here: its library entry lists “Strong GH pulse” and 4 of our study pages are about this goal.
GHRP-6
#4 · Human studiesOne of the first growth hormone releasing peptides, with one standout effect: strong appetite stimulation. First-generation GH secretagogue that stimulates GH via ghrelin receptor activation. For growth hormone it has been studied in people: 3 of our study pages in people are about it.
GHRP-6 raised night GH, ACTH, cortisol and stage 2 sleep in menOur study page: randomized trial in people, 1995
- GHRP-6 + GHRH: high blood sugar cut GH response in type 2 diabetes
- GHRP-6: weaker growth hormone release in thyrotoxicosis vs controls
Why it is here: its library entry lists “GH release” and 3 of our study pages are about this goal.
MK-677
#5 · Human studiesNot actually a peptide — it's a small molecule you take orally that mimics ghrelin to stimulate GH release. Once-daily dosing boosts natural GH pulses and keeps IGF-1 elevated. For growth hormone it has been studied in people: 3 of our study pages in people are about it.
MK-677 raised IGF-1 but not most function after hip fractureOur study page: randomized trial in people, 123 people, 2011
- MK-677: IGF-I rose 52% at 10 mg and 79% at 50 mg in GH-deficient men
- MK-677: moderate GH isoform shifts over 8 weeks in obese men
Why it is here: its library entry lists “Oral GH boost” and 3 of our study pages are about this goal.
CJC-1295 with DAC
#6 · Human studiesA long-acting growth hormone releasing hormone analogue: the DAC modification extends its half-life to about a week, so one weekly injection keeps GH and IGF-1 raised, lifting baseline GH while natural pulses continue. In human studies one injection raised baseline GH and IGF-1 for days while natural GH pulses continued; recovery, body-composition and sleep effects are extrapolated from GH physiology and user reports. For growth hormone it has been studied in people: 2 of our study pages in people are about it, beside 1 animal or lab study (rats).
CJC-1295 with DAC: one shot raised GH 2- to 10-fold in healthy adultsOur study page: randomized trial in people, 2006
- CJC-1295 with DAC: trough GH up 7.5-fold, pulses kept in healthy men
- CJC-1295 with DAC: 4-fold larger GH response than hGRF(1-29) in rats
Why it is here: its library entry lists “Sustained GH” and “IGF-1 elevation” and 3 of our study pages are about this goal.
Dulaglutide
#7 · Human studiesA weekly GLP-1 pen (Trulicity) for type 2 diabetes: it lowers blood sugar and, in people at cardiovascular risk, the combined risk of heart attack, stroke and cardiovascular death, and it comes in four ready-dosed pens. For growth hormone it has been studied in people: 1 of our study pages in people is about it.
GHRP-2 plus L-arginine gave the biggest GH rise during exerciseOur study page: clinical trial in people, 2000
Why it is here: 1 of our study pages is about this goal.
Tesamorelin
#8 · Human studiesThe only GHRH analog currently FDA-approved (to reduce excess abdominal fat in HIV lipodystrophy). Stimulates GH secretion, reduces visceral adiposity, and improves body composition. For growth hormone it has been studied in people: 1 of our study pages in people is about it.
Tesamorelin: model accurately predicted GH and IGF-1 over 14 daysOur study page: clinical trial in people, 41 people, 2015
Why it is here: 1 of our study pages is about this goal.
Clomiphene
#9 · Human studiesAn oral pill that blocks estrogen's signal in the brain, so the body makes more of its own LH and FSH, and with them testosterone and sperm. It blocks estrogen's feedback signal at the hypothalamus and pituitary, so the brain reads estrogen as low and sends out more LH and FSH; in men that raises the testes' own testosterone and supports sperm production, the opposite of TRT, which shuts both down. For growth hormone it has been studied in people: 1 of our study pages in people is about it.
Clomiphene: IGF-1 fell 41% in men with uncontrolled acromegalyOur study page: clinical trial in people, 16 people, 2015
Why it is here: 1 of our study pages is about this goal.
Sermorelin
#10 · Human studiesA synthetic copy of the first 29 amino acids of your natural growth hormone releasing hormone: it prompts your pituitary to release its own GH, keeping the body's feedback loops in play. It was FDA-approved as a diagnostic test (1990) and to treat GH deficiency in children (1997) until the maker discontinued it in 2008, not for safety reasons. For growth hormone the trials in people that its library entry cites put it on this rung, though none of our study pages covers this goal yet.
The library’s research note “What Sermorelin is built on” rests on studies in people.
Why it is here: its library entry lists “Natural GH boost”.
Ipamorelin
#11 · Human studiesConsidered the 'cleanest' growth hormone stimulator: in animal studies it triggers the pituitary to release GH without raising cortisol, a side effect common with other GH peptides. Its human data are a small GH study and phase 2 trials in surgical patients; it was never approved. For growth hormone the trials in people that its library entry cites put it on this rung; our 3 study pages on it for this goal are animal or lab studies (rats, swine and dogs).
The library’s research note “What Ipamorelin is built on” rests on studies in people.
Ipamorelin for 21 days raised pituitary secretion granules in ratsOur study page: animal study in rats, 2002
- Ipamorelin: new derivative matched its GH potency in swine
- Ipamorelin released GH without raising ACTH or cortisol in swine
Why it is here: its library entry lists “GH release” and 3 of our study pages are about this goal.
CJC-1295 no DAC
#12 · Human studiesThe shorter-acting version of CJC-1295, meant to give sharp, pulse-like GH release. Almost always stacked with Ipamorelin: together they release more GH than either alone, a synergy well established for the two drug classes. For growth hormone the trials in people that its library entry cites put it on this rung, though none of our study pages covers this goal yet.
The library’s research note “What CJC-1295 no DAC is built on” rests on studies in people.
Why it is here: its library entry lists “Pulsatile GH”.
Animal or lab studies only
1 compound
IGF-1 LR3
#13 · Animal or labIGF-1 is the growth factor your liver and muscles make when growth hormone arrives — the messenger that does much of GH's building work. IGF-1 LR3 is a lab-modified copy designed to slip past the proteins that normally hold IGF-1 in reserve, which makes it several times more potent in a dish and in rats, and also makes it clear faster. For growth hormone the evidence is from animals or cells only: 4 study pages of ours, in pigs, marmoset monkeys, guinea pigs and rats.
IGF-1 LR3 lowered blood sugar longer than native IGF-I in pigsOur study page: animal study in pigs and marmoset monkeys, 1997
- IGF-1 LR3 raised organ weights but not growth in guinea pigs
- IGF-1 LR3: several times as potent as IGF-I for gut growth in rats
- IGF-1 LR3: about 2.5-fold more potent than IGF-I in catabolic rats
Why it is here: its library entry lists “IGF-1 pathway” and 4 of our study pages are about this goal.
How they differ
Route, dosing frequency and half-life as each library entry records them, for the 13 compounds in ranked order.
| Compound | Evidence | Route | Dosing frequency | Half-life |
|---|---|---|---|---|
| HGH | FDA-approved | SubQ injection | Daily SubQ injection. | ~3-4 hours |
| GHRP-2 | Human studies | SubQ injection | 2–3x daily | ~30 min |
| Hexarelin | Human studies | SubQ injection | 2–3x daily | ~55–70 min |
| GHRP-6 | Human studies | SubQ injection | 2–3x daily | ~20 min |
| MK-677 | Human studies | Oral | Daily, before bed | ~24 hours |
| CJC-1295 with DAC | Human studies | SubQ injection | Weekly | ~6–8 days |
| Dulaglutide | Human studies | SubQ injection | Weekly | ~5 days |
| Tesamorelin | Human studies | SubQ injection | Daily | ~8–11 min |
| Clomiphene | Human studies | Oral tablet | Daily or every other day | ~5 days |
| Sermorelin | Human studies | SubQ injection | Daily, before bed | ~11–12 min |
| Ipamorelin | Human studies | SubQ injection, IM injection | 2–3x daily, best fasted or before bed | ~2 hours |
| CJC-1295 no DAC | Human studies | SubQ injection | 2–3x daily | ~30 min |
| IGF-1 LR3 | Animal or lab | SubQ injection | Daily (community protocols: training days) | Not measured in people: no human pharmacokinetic study of IGF-1 LR3 has been published. In rats it cleared from plasma about ten times faster than IGF-1 |
- Evidence
- FDA-approved
- Route
- SubQ injection
- Dosing
- Daily SubQ injection.
- Half-life
- ~3-4 hours
- Evidence
- Human studies
- Route
- SubQ injection
- Dosing
- 2–3x daily
- Half-life
- ~30 min
- Evidence
- Human studies
- Route
- SubQ injection
- Dosing
- 2–3x daily
- Half-life
- ~55–70 min
- Evidence
- Human studies
- Route
- SubQ injection
- Dosing
- 2–3x daily
- Half-life
- ~20 min
- Evidence
- Human studies
- Route
- Oral
- Dosing
- Daily, before bed
- Half-life
- ~24 hours
- Evidence
- Human studies
- Route
- SubQ injection
- Dosing
- Weekly
- Half-life
- ~6–8 days
- Evidence
- Human studies
- Route
- SubQ injection
- Dosing
- Weekly
- Half-life
- ~5 days
- Evidence
- Human studies
- Route
- SubQ injection
- Dosing
- Daily
- Half-life
- ~8–11 min
- Evidence
- Human studies
- Route
- Oral tablet
- Dosing
- Daily or every other day
- Half-life
- ~5 days
- Evidence
- Human studies
- Route
- SubQ injection
- Dosing
- Daily, before bed
- Half-life
- ~11–12 min
- Evidence
- Human studies
- Route
- SubQ injection, IM injection
- Dosing
- 2–3x daily, best fasted or before bed
- Half-life
- ~2 hours
- Evidence
- Human studies
- Route
- SubQ injection
- Dosing
- 2–3x daily
- Half-life
- ~30 min
- Evidence
- Animal or lab
- Route
- SubQ injection
- Dosing
- Daily (community protocols: training days)
- Half-life
- Not measured in people: no human pharmacokinetic study of IGF-1 LR3 has been published. In rats it cleared from plasma about ten times faster than IGF-1
Compared side by side
- CJC-1295 no DAC vs Ipamorelin
- CJC-1295 with DAC vs CJC-1295 no DAC
- Sermorelin vs Tesamorelin
- Ipamorelin vs Sermorelin
- Ipamorelin vs MK-677
- GHRP-2 vs GHRP-6
- Ipamorelin vs GHRP-2
- Ipamorelin vs GHRP-6
- Ipamorelin vs Hexarelin
- CJC-1295 with DAC vs Ipamorelin
- CJC-1295 no DAC vs Sermorelin
- Ipamorelin vs Tesamorelin
- MK-677 vs CJC-1295 no DAC
- HGH vs Sermorelin
- HGH vs MK-677
- HGH vs Tesamorelin
- HGH vs IGF-1 LR3
- HGH vs Ipamorelin
Questions
Which peptides have been studied in people for growth hormone?
12 of the 13 on this page: HGH, GHRP-2, Hexarelin, GHRP-6, MK-677, CJC-1295 with DAC, Dulaglutide, Tesamorelin, Clomiphene, Sermorelin, Ipamorelin and CJC-1295 no DAC. The rest have animal or lab evidence or community reports only.
Is any peptide FDA-approved for growth hormone?
HGH: the library records an FDA approval for a related use (HGH: FDA-approved since the 1980s for GH deficiency and several growth disorders, but not for aging or athletic use: in healthy adults, trials show about 2 kg of fat swapped for lean mass, with no strength gain and more side effects).
Which is the best-studied peptide for growth hormone?
By our count, GHRP-2, with 4 study pages in people about growth hormone, the most of any compound here.
Which ones have only animal or lab evidence for growth hormone?
1 compound: IGF-1 LR3 (pigs and marmoset monkeys, guinea pigs and rats). A result in animals or cells often doesn’t hold in people.
How are the peptides for growth hormone taken?
Of the 13 compounds for growth hormone, 11 are taken by injection, 2 by mouth, as their library entries list (some have more than one route). The table above gives each one’s route, how often it is dosed and its half-life.
How do the peptides for growth hormone compare with each other?
We compare 18 pairs of them side by side: CJC-1295 no DAC vs Ipamorelin, CJC-1295 with DAC vs CJC-1295 no DAC, Sermorelin vs Tesamorelin, Ipamorelin vs Sermorelin, Ipamorelin vs MK-677, GHRP-2 vs GHRP-6, Ipamorelin vs GHRP-2, Ipamorelin vs GHRP-6, Ipamorelin vs Hexarelin, CJC-1295 with DAC vs Ipamorelin, CJC-1295 no DAC vs Sermorelin, Ipamorelin vs Tesamorelin, MK-677 vs CJC-1295 no DAC, HGH vs Sermorelin, HGH vs MK-677, HGH vs Tesamorelin, HGH vs IGF-1 LR3 and HGH vs Ipamorelin.
How we ranked them
Each compound is placed on the highest rung its evidence for this goal reaches. First come compounds the FDA has approved for a use related to the goal, and only where the library entry says so. Next come compounds studied in people for it (in one of our study pages, or in the trials a research note of the library entry rests on), then those with animal or lab studies only, and last those resting on community reports alone.
Within a rung, compounds are ordered by how many of our study pages in people cover the goal, then by the library’s overall research rating, then by the number of study pages of any kind. A compound is on this page only because its library entry lists a use for this goal, says so in its description, or one of our study pages is about it; the reason is printed with each one.
This is a ranking of evidence, not of results, and not advice on what anyone should take.